MediPharm Labs Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for MediPharm Labs.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth58.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2023

Recent future growth updates

Recent updates

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07
Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11
Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Earnings and Revenue Growth Forecasts

TSX:LABS - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202442-8N/AN/A2
12/31/202333-13-13-12N/A
9/30/202330-16-15-14N/A
6/30/202328-19-14-14N/A
3/31/202323-26-14-14N/A
12/31/202222-30-17-16N/A
9/30/202222-46-21-20N/A
6/30/202220-46-18-17N/A
3/31/202221-48-13-13N/A
12/31/202122-55-14-13N/A
9/30/202122-64-17-16N/A
6/30/202122-72-27-26N/A
3/31/202130-63-33-28N/A
12/31/202036-66-45-38N/A
9/30/202062-39-46-29N/A
6/30/2020101-20-67-40N/A
3/31/2020118-15-74-45N/A
12/31/20191292-58-25N/A
9/30/20191071-54-27N/A
6/30/201964-4-36-12N/A
3/31/201932-8-23-4N/A
12/31/201810-8-26-11N/A
9/30/2018N/A-6-23-10N/A
6/30/2018N/A-4-9-4N/A
3/31/2018N/A-2-7-3N/A
12/31/2017N/A-1-20N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LABS's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if LABS's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if LABS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LABS's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if LABS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LABS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.